[New therapeutic prospects in autosomal dominant polycystic kidney disease].

Correspondence: Roser Torra Enfermedades Renales Hereditarias Servicio de Nefrología Fundació Puigvert Barcelona [email protected] INTRODUCTION Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of ESRD in adults. There is currently no specific treatment for ADPKD, but great progress has been made in recent years in understanding of the cystogenesis process and the pathogenesis of the disease. There is clear evidence supporting a predominant role of proliferation of epithelial cells, transepithelial fluid secretion, and extracellular matrix remodelling. Various therapeutic approaches to ADPKD are being tested based on this evidence and using renal volume progression as efficacy parameter (table I).